全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用：99美元
投递稿件

查看量下载量

相关文章

更多...

粒细胞肉瘤6例
6 Cases of Granulosa Sarcoma

DOI: 10.12677/ACM.2020.107189, PP. 1239-1245

Keywords: 粒细胞肉瘤，诊断，鉴别诊断，治疗，预后，急性髓系白血病
Granulocytic Sarcoma, Diagnosis, Differential Diagnosis, Treatment, Prognosis, Acute Myeloid Leukemia

Full-Text   Cite this paper   Add to My Lib

Abstract:

目的：探讨粒细胞肉瘤(Granulocytic Sarcoma; GS)的诊断、鉴别诊断及治疗。方法：回顾性分析青岛大学附属医院自2000年6月至2019年6月收治的6例GS的临床资料中，男2例，女4例，中位年龄51.7岁(37~66岁)，其中孤立性粒细胞肉瘤5例，髓外浸润性粒细胞肉瘤1例，讨论其临床病理特征、诊断及治疗。结果：6例GS临床表现多样，首发表现为肿物伴或者不伴有疼痛，免疫组化MPO、CD68、CD113、CD117等阳性率较高，治疗上以联合化疗为主。结论：GS临床误诊率很高，免疫组化具有特异性，易转化为急性髓系白血病，预后差。
Objective: To explore the diagnosis, differential diagnosis and treatment of granulocytic sarcoma (GS). Methods: Retrospective analysis of the clinical data of 6 cases of GS admitted to the Affiliated Hospital of Qingdao University from June 2000 to June 2019, including 2 males and 4 females, with a median age of 55 years (37 - 66 years), including isolation. There were 5 cases of granulosa sarcoma and 1 case of extramedullary infiltrating granulosa sarcoma. The clinicopathological characteristics, diagnosis and treatment were discussed. Results: Six cases of GS have various clinical manifestations, the first manifestation is tumor with or without pain, and the immunohistochemical MPO, CD68, CD113, CD117 and other positive rates are high, the main treatment is combined chemotherapy. Conclusion: The clinical misdiagnosis rate of GS is very high, immunohistochemistry is specific, it is easy to be transformed into acute myeloid leukemia, and the prognosis is poor.

References

[1]  Sabattini, E., Bacci, F., Sagramoso, C., et al. (2010) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues in 2008: An Overview. Pathologica, 102, 83-87.
[2]  Kaur, V., Swami, A., Alapat, D., et al. (2018) Clinical Characteristics, Molecular Profile and Outcomes of Myeloid Sarcoma: A Single Institution Experience over 13 Years. Hematology, 23, 17-24.
https://doi.org/10.1080/10245332.2017.1333275
[3]  Almond, L.M., Charalampakis, M., Ford, S.J., et al. (2017) Myeloid Sarcoma: Presentation, Diagnosis, and Treatment. Clinical Lymphoma, Myeloma & Leukemia, 17, 263-267.
https://doi.org/10.1016/j.clml.2017.02.027
[4]  Campidelli, C., Agostinelli, C., Stitson, R., et al. (2009) Myeloid Sarcoma: Extramedullary Manifestation of Myeloid Disorders. American Journal of Clinical Pathology, 132, 426-437.
https://doi.org/10.1309/AJCP1ZA7HYZKAZHS
[5]  Peloquin, G.L., Chen, Y.-B. and Fathi, A.T. (2013) The Evolving Landscape in the Therapy of Acute Myeloid Leukemia. Protein & Cell, 4, 735-746.
https://doi.org/10.1007/s13238-013-3057-2
[6]  Pui, M.H., Fletcher, B.D. and Langston, J.W. (1994) Granulocytic Sarcoma in Childhood Leukemia: Imaging Features. Radiology, 190, 698-702.
https://doi.org/10.1148/radiology.190.3.8115614
[7]  Singh, A., Kumar, P., Chandrashekhara, S.H., et al. (2017) Unravelling Chloroma: Review of Imaging Findings. The British Journal of Radiology, 90, 20160710.
https://doi.org/10.1259/bjr.20160710
[8]  Kamboj, M., Sharma, A., Gupta, G., et al. (2017) Isolated Myeloid Sarcoma of Cervix: Aleukemic Presentation. Journal of Cancer Research and Therapeutics, 13, 1076-1077.
[9]  Claerhout, H., Van Aelst, S., Melis, C., et al. (2018) Clinicopathological Characteristics of de Novo and Secondary Myeloid Sarcoma: A Monocentric Retrospective Study. European Journal of Haematology, 100, 603-612.
https://doi.org/10.1111/ejh.13056
[10]  Neiman, R.S., Barcos, M., Berard, C., et al. (1981) Granulocytic Sarcoma: A Clinicopathologic Study of 61 Biopsied Cases. Cancer, 48, 1426-1437.
https://doi.org/10.1002/1097-0142(19810915)48:6<1426::AID-CNCR2820480626>3.0.CO;2-G
[11]  Meyer, H.-J., Beimler, M., Borte, G., et al. (2019) Radiological and Clinical Patterns of Myeloid Sarcoma. Radiology and Oncology, 53, 213-218.
https://doi.org/10.2478/raon-2019-0014
[12]  Aschoff, P., H？ntschel, M., Oksüz, M., et al. (2009) Integrated FDG-PET/CT for Detection, Therapy Monitoring and Follow-Up of Granulocytic Sarcoma. Initial Results. Nuklearmedizin, 48, 185-191.
https://doi.org/10.3413/nukmed-0236
[13]  Zhang, X., Huang, P., Chen, Z., et al. (2019) Vulvar Myeloid Sarcoma as the Presenting Symptom of Acute Myeloid Leukemia: A Case Report and Literature Review of Chinese Patients, 1999-2018. Diagnostic Pathology, 14, Article No.: 126.
https://doi.org/10.1186/s13000-019-0892-3
[14]  Pileri, S.A., Ascani, S., Cox, M.C., et al. (2007) Myeloid Sarcoma: Clinico-Pathologic, Phenotypic and Cytogenetic Analysis of 92 Adult Patients. Leukemia, 21, 340-350.
https://doi.org/10.1038/sj.leu.2404491
[15]  Alexiev, B.A., Wang, W., Ning, Y., et al. (2007) Myeloid Sarcomas: A Histologic, Immunohistochemical, and Cytogenetic Study. Diagnostic Pathology, 2, Article No.: 42.
https://doi.org/10.1186/1746-1596-2-42
[16]  Bakst, R.L., Tallman, M.S., Douer, D., et al. (2011) How I Treat Extramedullary Acute Myeloid Leukemia. Blood, 118, 3785-3793.
https://doi.org/10.1182/blood-2011-04-347229
[17]  Tsimberidou, A.-M., Kantarjian, H.M., Wen, S., et al. (2008) Myeloid Sarcoma Is Associated with Superior Event- Free Survival and Overall Survival Compared with Acute Myeloid Leukemia. Cancer, 113, 1370-1378.
https://doi.org/10.1002/cncr.23691
[18]  Yamauchi, K. and Yasuda, M. (2002) Comparison in Treatments of Nonleukemic Granulocytic Sarcoma: Report of Two Cases and a Review of 72 Cases in the Literature. Cancer, 94, 1739-1746.
https://doi.org/10.1002/cncr.10399
[19]  Florou, V. and Wilky, B.A. (2018) Current and Future Directions for Angiosarcoma Therapy. Current Treatment Options in Oncology, 19, Article No.: 14.
https://doi.org/10.1007/s11864-018-0531-3
[20]  Shelley, M.D., Mason, M.D. and Kynaston, H. (2010) Intravesical Therapy for Superficial Bladder Cancer: A Systematic Review of Randomised Trials and Meta-Analyses. Cancer Treatment Reviews, 36, 195-205.
https://doi.org/10.1016/j.ctrv.2009.12.005
[21]  Bielack, S.S., Erttmann, R., Kempf-Bielack, B., et al. (1996) Impact of Scheduling on Toxicity and Clinical Efficacy of Doxorubicin: What Do We Know in the Mid-Nineties? European Journal of Cancer, 32A, 1652-1660.
https://doi.org/10.1016/0959-8049(96)00177-3
[22]  Skubitz, K.M. and Haddad, P.A. (2005) Paclitaxel and Pegylated-Liposomal Doxorubicin Are Both Active in Angiosarcoma. Cancer, 104, 361-366.
https://doi.org/10.1002/cncr.21140
[23]  Lan, T.-Y., Lin, D.-T., Tien, H.-F., et al. (2009) Prognostic Factors of Treatment Outcomes in Patients with Granulocytic Sarcoma. Acta Haematologica, 122, 238-246.
https://doi.org/10.1159/000253592
[24]  Chevallier, P., Mohty, M., Lioure, B., et al. (2008) Allogeneic Hematopoietic Stem-Cell Transplantation for Myeloid Sarcoma: A Retrospective Study from the SFGM-TC. Journal of Clinical Oncology, 26, 4940-4943.
https://doi.org/10.1200/JCO.2007.15.6315
[25]  林桂真. 自体与异体造血干细胞移植后造血系统重建的状况与差异分析[J]. 新医学, 2005, 36(5): 277-278.
[26]  Avni, B. and Koren-Michowitz, M. (2011) Myeloid Sarcoma: Current Approach and Therapeutic Options. Therapeutic Advances in Hematology, 2, 309-316.
https://doi.org/10.1177/2040620711410774
[27]  He, J., Zhu, L., Ye, X., et al. (2014) Clinical Characteristics and Prognosis of Nonleukemic Myeloid Sarcoma. The American Journal of the Medical Sciences, 347, 434-438.
https://doi.org/10.1097/MAJ.0b013e31829ca859

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133